EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antiamoebic Activity of Rutamycin B and Inhibition of Naegleria fowleri F1FO ATP Synthase Activity

Hayley Fong, Elkay Galang, Reiko Iizumi, William Fenical, Anjan Debnath

Marine Drugs · 26.10.2026 · 24 (11) · 379

DOI: 10.3390/md24110379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 26.10.2026. Verfasst von Hayley Fong und 4 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Naegleria fowleri induces fatal human infection known as primary amoebic meningoencephalitis (PAM). Currently, the recommended treatment does not guarantee uniform survival. Thus, there is an urgent need to find an effective and fast-acting treatment for PAM. Our previous study identified anti-N. fowleri activity of marine microbial metabolite mixtures. We recently isolated a pure compound rutamycin B from an amoebicidal metabolite. We sought to determine the activity of rutamycin B and to identify its target in N. fowleri. We determined the dose–response of rutamycin B against N. fowleri and two mammalian cells and measured potency at different time points. We investigated the combined effect of rutamycin B and amphotericin B on both N. fowleri and mammalian cells. For target identification in N. fowleri, we (i) determined the mitochondrial ATP synthase activity of N. fowleri treated with rutamycin B, and (ii) quantified the production of intracellular reactive oxygen species (ROS) in the presence of the compound. Rutamycin B exhibited potency between 0.02 and 0.3 µM against five strains of N. fowleri and had a selectivity index of 200–300. It achieved nanomolar potency on all five strains within four hours, and the combination of rutamycin B with amphotericin B was synergistic without eliciting toxicity on mammalian cells. Significant inhibition of N. fowleri ATP synthase activity and subsequent ROS production suggest that rutamycin B may target F1FO ATP synthase of the pathogen. Our findings identified a potent marine-derived compound and its potential target in N. fowleri and support further pharmacological studies of rutamycin B for the treatment of PAM.

Förderung

  • National Institutes of Health

Zitieren

APA

Fong, H., Galang, E., Iizumi, R., Fenical, W., & Debnath, A. (2026). Antiamoebic Activity of Rutamycin B and Inhibition of Naegleria fowleri F1FO ATP Synthase Activity. Marine Drugs, 24(11), 379. https://doi.org/10.3390/md24110379

Vancouver

Fong H, Galang E, Iizumi R, Fenical W, Debnath A. Antiamoebic Activity of Rutamycin B and Inhibition of Naegleria fowleri F1FO ATP Synthase Activity. Marine Drugs. 2026;24(11):379. doi:10.3390/md24110379

BibTeX
@article{Fong2026,
  author = {Fong, Hayley and Galang, Elkay and Iizumi, Reiko and Fenical, William and Debnath, Anjan},
  title = {Antiamoebic Activity of Rutamycin B and Inhibition of Naegleria fowleri F1FO ATP Synthase Activity},
  journal = {Marine Drugs},
  year = {2026},
  volume = {24},
  number = {11},
  pages = {379},
  doi = {10.3390/md24110379}
}
Kostenlos starten →